Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
67
CSPCY Quote, Financials, Valuation and Earnings
Last price:
$4.45
Seasonality move
:
13.1%
Day range:
$4.41 - $4.45
52-week range:
$2.15 - $5.83
Dividend yield:
2.79%
P/E ratio:
23.76x
P/S ratio:
3.53x
P/B ratio:
15.44x
Volume:
325
Avg. volume:
12.2K
1-year change:
80.99%
Market cap:
$12.6B
Revenue:
$4B
EPS (TTM):
$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
$4.41 | -- | $12.6B | 23.76x | $0.07 | 2.79% | 3.53x |
|
ADAG
Adagene, Inc.
|
$1.85 | $9.22 | $87.2M | -- | $0.00 | 0% | 832.60x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.78 | $4.00 | $16.1M | -- | $0.00 | 0% | 0.46x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.31 | -- | $4.3M | -- | $0.00 | 0% | 1.06x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$18.58 | $49.17 | $2.1B | -- | $0.00 | 0% | 4.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
1.2% | 0.524 | -- | 1.93x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
$646.8M | $205.9M | 12.94% | 12.37% | 25.7% | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
CSPC Pharmaceutical Group Ltd. vs. Competitors
-
Which has Higher Returns CSPCY or ADAG?
Adagene, Inc. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of --. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About CSPCY or ADAG?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 398.61%. Given that Adagene, Inc. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe Adagene, Inc. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is CSPCY or ADAG More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.625, which suggesting that the stock is 37.462% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CSPCY or ADAG?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.79%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or ADAG?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Adagene, Inc. quarterly revenues of --. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Adagene, Inc.'s net income of --. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.76x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.53x versus 832.60x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.53x 23.76x $964.2M $203.2M ADAGAdagene, Inc.832.60x -- -- --
-
Which has Higher Returns CSPCY or CASI?
CASI Pharmaceuticals, Inc. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of -353.92%. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About CSPCY or CASI?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 411.51%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is CSPCY or CASI More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.625, which suggesting that the stock is 37.462% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock CSPCY or CASI?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.79%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or CASI?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.76x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.53x versus 0.46x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.53x 23.76x $964.2M $203.2M CASICASI Pharmaceuticals, Inc.0.46x -- $3.1M -$10.9M
-
Which has Higher Returns CSPCY or CPHI?
China Pharma Holdings, Inc. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of -86.16%. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About CSPCY or CPHI?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSPC Pharmaceutical Group Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe CSPC Pharmaceutical Group Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is CSPCY or CPHI More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.625, which suggesting that the stock is 37.462% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock CSPCY or CPHI?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.79%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or CPHI?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.76x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.53x versus 1.06x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.53x 23.76x $964.2M $203.2M CPHIChina Pharma Holdings, Inc.1.06x -- $756.2K -$651.5K
-
Which has Higher Returns CSPCY or SVA?
Sinovac Biotech Ltd. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of --. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About CSPCY or SVA?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSPC Pharmaceutical Group Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe CSPC Pharmaceutical Group Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is CSPCY or SVA More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.625, which suggesting that the stock is 37.462% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock CSPCY or SVA?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.79%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or SVA?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.76x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.53x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.53x 23.76x $964.2M $203.2M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns CSPCY or ZLAB?
Zai Lab Ltd. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of -30.98%. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About CSPCY or ZLAB?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 164.64%. Given that Zai Lab Ltd. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe Zai Lab Ltd. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is CSPCY or ZLAB More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.625, which suggesting that the stock is 37.462% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock CSPCY or ZLAB?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.79%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or ZLAB?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Zai Lab Ltd. quarterly revenues of $116.2M. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.76x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.53x versus 4.51x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.53x 23.76x $964.2M $203.2M ZLABZai Lab Ltd.4.51x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
